COMPASS Pathways plc (NASDAQ:CMPS) Receives Average Recommendation of “Buy” from Analysts

Shares of COMPASS Pathways plc (NASDAQ:CMPS) have earned an average recommendation of “Buy” from the seven ratings firms that are covering the stock, Marketbeat reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have covered the stock in the last year is $21.83.

Several equities research analysts have weighed in on the stock. Stifel Nicolaus started coverage on shares of COMPASS Pathways in a report on Thursday, February 27th. They issued a “buy” rating and a $11.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price objective on shares of COMPASS Pathways in a research note on Tuesday. Canaccord Genuity Group reduced their target price on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, February 28th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $18.00 price target on shares of COMPASS Pathways in a report on Wednesday, January 15th.

COMPASS Pathways Price Performance

CMPS opened at $3.85 on Wednesday. The company has a fifty day moving average price of $4.05 and a two-hundred day moving average price of $5.19. The firm has a market capitalization of $263.42 million, a PE ratio of -1.75 and a beta of 2.28. COMPASS Pathways has a 52 week low of $3.17 and a 52 week high of $11.90. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91.

COMPASS Pathways (NASDAQ:CMPS) last posted its earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). As a group, analysts anticipate that COMPASS Pathways will post -2.33 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. RTW Investments LP acquired a new stake in COMPASS Pathways in the 4th quarter valued at $11,714,000. Altium Capital Management LLC acquired a new stake in shares of COMPASS Pathways in the fourth quarter valued at about $5,384,000. Tang Capital Management LLC acquired a new stake in shares of COMPASS Pathways in the fourth quarter valued at about $3,780,000. Nantahala Capital Management LLC raised its holdings in COMPASS Pathways by 400.0% during the fourth quarter. Nantahala Capital Management LLC now owns 1,000,000 shares of the company’s stock worth $3,780,000 after acquiring an additional 800,000 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new position in COMPASS Pathways during the fourth quarter valued at approximately $2,458,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.